LLY stock jumps after FDA approves Eli Lilly’s tirzepatide drug for weight loss

November 08, 2023 11:14 AM PST | By Invezz
Follow us on Google News:

Eli Lilly And Co’s (NYSE: LLY) stock saw a notable surge, trading at $610.50, up 1.69% (+$10.14) today, following the Food and Drug Administration’s (FDA) approval of their blockbuster drug tirzepatide for weight loss.

Eli Lilly is a major player in the pharmaceutical industry and the approval opens the door for a wider range of applications for this medication, marketed as Zepbound, in the United States.

LLY stock price movement

Today’s LLY stock price surge reflects the market’s positive response to the FDA’s decision.

However, the stock’s day range extended from $592.18 to $613.00, showcasing significant intraday fluctuations. With a 52-week range of $309.20 to $629.97 and a market cap of $579.20 billion.

FDA approves Tirzepatide drug for weight loss

The FDA’s recent approval of Eli Lilly’s tirzepatide for weight loss marks a significant milestone for the pharmaceutical company.

Tirzepatide, initially approved in May 2022 for the treatment of Type 2 diabetes under the name Mounjaro, can now be used by adults who are overweight or obese and have at least one weight-related condition for chronic weight management, under the name Zepbound.

Before this FDA approval, many individuals were using tirzepatide off-label for weight loss, contributing to the high demand for weight loss treatments. This demand surge has also affected other weight loss medications in the market, such as Novo Nordisk’s Wegovy and Ozempic.

Eli Lilly’s move into the obesity drug market positions them as a strong competitor to Novo Nordisk. Analysts predict the obesity drug market could grow to a $100 billion industry by 2030. The increasing use of these drugs has raised questions about their broader industry impact.

With obesity affecting approximately 40% of the US adult population and an estimated 650 million adults globally, the FDA’s approval addresses a pressing medical need. The newly approved Zepbound is administered through weekly injections and requires gradual dosage adjustments to achieve target doses of 5, 10, or 15 milligrams per week.

While the approval is a significant development, access to tirzepatide and other obesity treatments remains a challenge, given the cost implications and the criteria set by insurance companies for coverage. Nevertheless, the market continues to evolve, with recent data suggesting potential long-lasting health benefits beyond weight loss.

The post LLY stock jumps after FDA approves Eli Lilly’s tirzepatide drug for weight loss appeared first on Invezz


The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.

Top Listed Companies